This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Take the CME quiz:
 Vol. 15 No. 1, January 2006
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Varma, S. K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Varma, S. K.
Related Collections
Right arrow Clinical Pharmacology and Therapeutics
Right arrow Endocrinology
Right arrow Bioethics

AAP Grand Rounds 15:9-10 (2006)
© 2006 American Academy of Pediatrics

ENDOCRINOLOGY

Long-Term Growth Hormone Treatment of Idiopathic Short Stature

Source: Kemp SF, Kuntze J, Attie KM, et al. Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature. J Clin Endocrinol Metab. 2005; 90:5247–5253.[Abstract/Free Full Text]

The first 20% of the full text of this article appears below.

These authors, including researchers from the University of Arkansas, Little Rock, and Genentech, Inc., South San Francisco, Calif., and consultants from the United States and Brazil, evaluated data from the observational National Cooperative Growth Study (NCGS), a multi-center postmarketing surveillance study established by Genentech in 1985 to evaluate the use, safety, and efficacy of Genentech’s biosynthetic human growth hormone (GH) products for the treatment of idiopathic short stature (ISS) in more than 8000 North American children. ISS is defined as short stature of unknown etiology in a child whose height is more than 2.25 Standard Deviation scores (SDS) below the mean and who is considered unlikely to reach a normal adult height. Data from these patients were assessed for safety, and efficacy analysis was performed on 3 subcohorts of patients based upon age and pubertal status at baseline. Patients were identified as having ISS if they met any of the following 3 criteria: a maximum stimulated growth hormone of 10 ng/ml or greater with text information confirming a physician diagnosis of ISS; a maximum stimulated GH of 10 ng/ml or greater and the . . . [Full Text of this Article]

Surendra K. Varma, MD, FAAP
Pediatrics, Texas Tech University Health Sciences Center, Lubbock, TX

 



This article has been cited by other articles:


Home page
 AAP Grand RoundsHome page
S. K. Varma
Growing Numbers for Idiopathic Short Stature Growth Hormone Therapy
AAP Grand Rounds, February 1, 2007; 17(2): 19 - 20.
[Full Text] [PDF]